** Shares of gene therapy maker Sarepta Therapeutics SRPT.O fall 21.3% to $36.80 in aftermarket trade
** Company sees 2025 net product revenue of $2.3 billion to $2.6 billion, compared to previous expectation of $2.9 billion to $3.1 billion
** Company reports adjusted Q1 loss of $3.42/shr, vs analysts' average loss estimate of 95 cents/shr, according to data compiled by LSEG
** SRPT shares, along with those of other gene therapy developers, had plummeted earlier in the day after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research
** Up to last close, stock down 61.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。